To track how AML-associated mutations and mutated blood-cell populations change before diagnosis, and assess whether these patterns distinguish people who later develop AML.
Approach:
Longitudinal samples: Researchers analyzed annual blood samples from 47 women who later developed AML and 46 age-matched controls who remained free of blood cancer.
Mutation tracking: Using TETRIS-seq, the team tracked AML-associated mutations and changes in the size of blood-cell populations carrying them.
Risk analysis: The researchers also analyzed UK Biobank data to assess whether extensive expansion of mutated cell populations was associated with myeloid leukemia.
Key Findings:
In about two-thirds of participants who developed AML, the first cancer-associated mutation was estimated to have appeared before age 20.
Mutated cell populations initially grew slowly; their growth accelerated as additional mutations accumulated, sometimes decades before clinical diagnosis.
Age-related mutations occurred in both groups, but future AML cases showed more extensive expansion and competition among mutated cell populations.
UK Biobank analysis found substantially increased odds of myeloid leukemia among individuals with evidence of extensive expansion of a mutated cell population.
Interpretation:
The findings suggest that assessing the extent of mutated-cell expansion, in addition to identifying mutations, may improve molecular risk assessment. The study does not establish a screening test.
Limitations:
The cohort was relatively small and consisted of older women.
About one-fifth of AML cases showed little detectable warning before diagnosis.
Further validation is needed to determine whether monitoring these changes can reliably identify high-risk individuals or guide preventive intervention.
Conclusion:
The study describes AML-associated genetic changes that can begin decades before diagnosis, while noting that the findings require further validation.